Drug Profile
Research programme: microRNA therapeutics - InteRNA Technologies
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator InteRNA Technologies
- Class Antineoplastics; MicroRNAs
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Bladder cancer; Cancer; Head and neck cancer; Pancreatic cancer
Highest Development Phases
- No development reported Bladder cancer; Head and neck cancer; Pancreatic cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Bladder-cancer in Netherlands
- 28 Aug 2020 No recent reports of development identified for research development in Head-and-neck-cancer in Netherlands
- 28 Aug 2020 No recent reports of development identified for research development in Pancreatic-cancer in Netherlands